IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023
- 14 November 2023 - 1 mins read
| Statement of transactions in own shares from November 06 to November 10, 2023 | BNP PARIBAS | |||||||||
| Aggregated presentation by day and by market | ||||||||||
| Name of issuer | Identification code of issuer (Legal Entity Identifier) | Day of transaction | Identification code of financial instrument | Aggregated daily volume (in number of shares) | Daily weighted average price of the purchased shares * | Market (MIC Code) | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 266 | 110.07 | AQEU | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 710 | 110.64 | CEUX | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 213 | 111.09 | TQEX | ||||
| IPSEN | 549300M6SGDPB4Z94P11 | 06/11/2023 | FR0010259150 | 2,630 | 110.49 | XPAR | ||||
| * Two-digit rounding after the decimal | TOTAL | 3,819 | 110.52 | |||||||
Attachment
13 November 2023
11 mins read
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...
07 November 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023
03 October 2023
5 mins read
Ipsen updates on QM-1114 regulatory process
26 September 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023
04 September 2023
5 mins read
Ipsen nominates Pascal Touchon to its Board of Directors as new independent director
21 August 2023
15 mins read
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
18 July 2023
1 mins read
IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023
26 May 2023
7 mins read
Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
09 June 2022
6 mins read
Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or...
27 October 2021
3 mins read